In chronic lymphocytic leukemia (CLL), BET inhibition restores T-cell proliferation and effector programs by reversing multi-receptor depletion, thus offering an important approach to overcome T-cell dysfunction under chronic inflammatory conditions [203]. This evidence concerns the gene DNER and B-cell chronic lymphocytic leukemia.